Generic Semaglutide Achieves Short-Term HbA1c Non-Inferiority, But Full Therapeutic Interchangeability Needs More Data

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by elevated blood glucose, often managed with GLP-1 receptor agonists like semaglutide. These agents effectively lower HbA1c and promote weight loss. As patents expire, generic versions emerge, raising critical questions about their therapeutic equivalence to reference products. While short-term non-inferiority for primary endpoints like glycemic control is a common regulatory benchmark, it doesn't always guarantee identical long-term safety, efficacy, or broader metabolic benefits, which is crucial for patient outcomes and healthcare decisions.

This clinical trial compared a generic semaglutide formulation against the reference product in patients with T2D. Participants received either generic or reference semaglutide via an identical once-weekly dose-escalation schedule, starting from 0.25 mg and titrating up to 2.4 mg. The study duration was 24 weeks. The primary endpoint was percentage weight change, with a non-inferiority margin of 5 percentage points, while HbA1c reduction, fasting and post-prandial glucose levels were also assessed as key secondary endpoints.

At Week 24, both generic and reference semaglutide achieved significant HbA1c reductions, with a mean decrease of -2.20%. Generic semaglutide successfully demonstrated non-inferiority to the reference product for HbA1c reduction.

Reductions in body weight, fasting glucose, and post-prandial glucose were similar between both treatment arms, further supporting the short-term equivalence. Specifically, the Least Squares Mean (LSM) for weight change was -11.25% for the generic product versus -11.25% for the reference. A substantial 86.62% of participants across both groups achieved the target HbA1c of <7.0%, indicating robust glycemic control. These findings suggest that, for key metabolic parameters over 24 weeks, the generic semaglutide performs comparably to the reference.